奥美拉唑、奥曲肽和凝血酶联合治疗肝硬化并发食管胃底静脉曲张破裂出血患者的临床疗效

doi:10.3969/j.issn.1671-7171.2022.03.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1103 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of omeprazole, octreotide and thrombin in the treatment of liver cirrhosis complicated with esophageal and gastric variceal bleeding. 【Methods】A total of 88 patients with liver cirrhosis complicated with esophageal and gastric variceal bleeding treated in our hospital from April 2018 to April 2021 were prospectively selected. They were randomly divided into observation group and control group, with 44 cases in each group. The control group was treated with omeprazole and octreotide, and the observation group was treated with thrombin on the basis of the control group. The therapeutic effects of the two groups were compared, and the hemostasis time, blood transfusion volume, symptom relief time, hospital stay and adverse reactions were observed.【Results】The total effective rate of the control group was 77.27% (34/44), which was significantly lower than 93.18% (41/44) in the observation group (χ²=4.423,P=0.035 < 0.05). The hemostasis time, symptom improvement time and hospitalization time of the observation group were shorter than those of the control group, and the amount of blood transfusion was lower than that of the control group (P<0.05). The incidence of adverse reactions in the control group was 9.09% (4/44), which was higher than 4.55% (2/44) in the observation group, but the difference was not statistically significant (χ²=4.062, P=0.443>0.05). 【Conclusion】The combination of omeprazole, octreotide and thrombin in the treatment of liver cirrhosis complicated with esophageal and gastric variceal bleeding has good clinical efficacy, good hemostatic effect, good safety and good prognosis.

Key words： Liver Cirrhosis/CO Liver Cirrhosis/DT Esophageal and Gastric Varices/DT Gastrointestinal Hemorrhage/ET Omeprazole/TU Octreotide/TU

Received: 31 July 2021

PACS:

R571.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PENG Xiong-qun
	YI Yan-rong
	GUO Hai-yan

Cite this article:

PENG Xiong-qun,YI Yan-rong,GUO Hai-yan. Clinical Efficacy of Omeprazole, Octreotide and Thrombin in the Treatment of Liver Cirrhosis Complicated with Esophageal and Gastric Variceal Bleeding[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 363-365.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.03.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I3/363

[1] 姚磊, 郑嵘炅, 邓泽润,等. 炎症因子动态变化在失代偿期肝硬化合并脓毒血症中的临床意义[J].新疆医学, 2019, 49(8):112-114.
[2] 丹珠永吉,刘芝兰,禄艳艳,等.内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究[J].实用肝脏病杂志,2019,22(5):692-695.
[3] 李国珍,周锦霞.奥曲肽联合奥美拉唑治疗肝炎后肝硬化合并上消化道出血患者的疗效及对止血时间及不良反应的影响[J].实用临床医药杂志,2017,21(9):49-51.
[4] 中华医学会外科学分会. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J].中华外科杂志, 2019,57(12):885-892.
[5] 王时峰,郭月皓,谢艳,等.奥美拉唑联合奥曲肽与胃镜辅助联合药物治疗胃出血患者的复发率差异研究[J].中国药物与临床,2019,19(6):860-862.
[6] 陈剑.奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的效果观察[J].医学理论与实践,2017,30(17):2565-2566.
[7] 周骁宇.奥曲肽联合凝血酶治疗肝硬化合并上消化道出血的临床效果研究[J].中国当代医药,2017,24(11):140-142.
[8] 周和荣,李杨.奥曲肽对食管胃底静脉曲张破裂出血的有效性[J].中国卫生标准管理,2021,12(4):115-117.
[9] 杜登泰,付曼荣,杨刚,等.奥美拉唑联合奥曲肽治疗肝硬化并上消化道出血的疗效评价[J].现代消化及介入诊疗,2018,23(5):633-635.
[10] MATHIEU D, BéATRICE D, OANEZ A, et al. Portal hypertension in children: High-risk varices, primary prophylaxis and consequences of bleeding[J].J Hepatol,2017, 66(2):320-327.
[11] KLEBER G, SAUERBRUCH T. Concomitant gastric varices: bleeding risk sign in patients with liver cirrhosis and esophageal varices[J].Gastroenterology,2018,70(33):1028-1034.